Ovarian Cancer
MK-2870-021: A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOT- ov85/GOG-3102)
- Details
ClinicalTrials.gov ID:
NCT07318558
Diagnosis Type:
NA
USOR Number:
- Address
,
P: